News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
This integrated center combines development, testing, evaluation, and industry-academia-research collaboration
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
With over two decades of extensive experience, Lal has established himself as a transformational leader in the FMCG and consumer goods sectors
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Subscribe To Our Newsletter & Stay Updated
